Pharmacological characterization of GABAA receptors in taurine-fed mice.
BACKGROUND
Taurine is one of the most abundant free amino acids especially in excitable tissues, with wide physiological actions. Chronic supplementation of taurine in drinking water to mice increases brain excitability mainly through alterations in the inhibitory GABAergic system. These changes include elevated expression level of glutamic acid decarboxylase (GAD) and increased levels of GABA. Additionally we reported that GABAA receptors were down regulated with chronic administration of taurine. Here, we investigated pharmacologically the functional significance of decreased / or change in subunit composition of the GABAA receptors by determining the threshold for picrotoxin-induced seizures. Picrotoxin, an antagonist of GABAA receptors that blocks the channels while in the open state, binds within the pore of the channel between the beta2 and beta3 subunits. These are the same subunits to which GABA and presumably taurine binds.


METHODS
Two-month-old male FVB/NJ mice were subcutaneously injected with picrotoxin (5 mg kg-1) and observed for a) latency until seizures began, b) duration of seizures, and c) frequency of seizures. For taurine treatment, mice were either fed taurine in drinking water (0.05%) or injected (43 mg/kg) 15 min prior to picrotoxin injection.


RESULTS
We found that taurine-fed mice are resistant to picrotoxin-induced seizures when compared to age-matched controls, as measured by increased latency to seizure, decreased occurrence of seizures and reduced mortality rate. In the picrotoxin-treated animals, latency and duration were significantly shorter than in taurine-treated animas. Injection of taurine 15 min before picrotoxin significantly delayed seizure onset, as did chronic administration of taurine in the diet. Further, taurine treatment significantly increased survival rates compared to the picrotoxin-treated mice.


CONCLUSIONS
We suggest that the elevated threshold for picrotoxin-induced seizures in taurine-fed mice is due to the reduced binding sites available for picrotoxin binding due to the reduced expression of the beta subunits of the GABAA receptor. The delayed effects of picrotoxin after acute taurine injection may indicate that the two molecules are competing for the same binding site on the GABAA receptor. Thus, taurine-fed mice have a functional alteration in the GABAergic system. These include: increased GAD expression, increased GABA levels, and changes in subunit composition of the GABAA receptors. Such a finding is relevant in conditions where agonists of GABAA receptors, such as anesthetics, are administered.
L'Amoreaux
William J
WJ
Department of Biology, College of Staten Island, 2800 Victory Blvd, Staten Island, NY 10314, USA. William.Lamoreaux@csi.cuny.edu
Marsillo
Alexandra
A
El Idrissi
Abdeslem
A
D000818:Animals; D001522:Behavior, Animal / Q000187:drug effects; D018756:GABA Antagonists / Q000494:pharmacology; D005968:Glutamate Decarboxylase / Q000378:metabolism; D008297:Male; D051379:Mice; D010852:Picrotoxin / Q000494:pharmacology; D011963:Receptors, GABA-A / Q000378:metabolism*; D012640:Seizures / Q000139:chemically induced; D013654:Taurine / Q000008:administration & dosage*; D005680:gamma-Aminobutyric Acid / Q000378:metabolism
D018756:GABA Antagonists; D005968:Glutamate Decarboxylase; D010852:Picrotoxin; D011963:Receptors, GABA-A; D013654:Taurine; D005680:gamma-Aminobutyric Acid
Expert Rev Neurother. 2006 Apr;6(4):575-89
16623656
J Neurochem. 1983 Aug;41(2):524-30
6875551
J Neurochem. 1993 Feb;60(2):395-407
8419527
Physiol Rev. 1993 Jan;73(1):119-47
8419963
Adv Exp Med Biol. 1992;315:263-8
1324594
Trends Pharmacol Sci. 1998 Dec;19(12):500-5
9871412
Br J Pharmacol. 2003 Mar;138(6):1163-71
12684273
J Pharmacol Exp Ther. 1967 Sep;157(3):546-54
6048015
FASEB J. 2004 Mar;18(3):511-8
15003996
Prog Neurobiol. 2000 Oct;62(2):113-34
10828380
Can J Physiol Pharmacol. 1968 Sep;46(5):803-4
5681539
Adv Exp Med Biol. 2009;643:199-206
19239150
J Neurochem. 2003 Aug;86(4):879-87
12887686
Dev Biol. 1992 Sep;153(1):158-64
1516745
Proc Natl Acad Sci U S A. 1982 May;79(10):3355-9
6124970
Proc Natl Acad Sci U S A. 2006 Mar 28;103(13):5185-90
16537435
Nature. 1962 Jan 20;193:301-2
13875057
Neuroscience. 2008 Oct 15;156(3):693-9
18727952
Exp Neurol. 2000 Feb;161(2):714-23
10686090
Prog Neurobiol. 1989;32(6):471-533
2664881
Neuroscience. 1985 Feb;14(2):375-403
2859548
J Neurochem. 1988 Sep;51(3):740-5
3411323
Comp Biochem Physiol B. 1973 Aug 15;45(4):741-8
4737979
Amino Acids. 2000;19(3-4):527-46
11140357
Brain Res. 1985 Jul 15;338(2):289-95
4027598
Neuropharmacology. 1995 Dec;34(12):1607-13
8788958
J Comp Neurol. 1999 Sep 27;412(3):488-505
10441235
Acta Neurochir Suppl (Wien). 1994;60:571-3
7976653
J Neurosci. 1998 Aug 1;18(15):5938-47
9671680
Dev Med Child Neurol. 1993 Mar;35(3):277
8462764
Synapse. 1997 Oct;27(2):122-32
9266773
Adv Exp Med Biol. 2000;483:213-8
11787600
Adv Exp Med Biol. 1998;442:329-37
9635048
Neurochem Res. 2004 Jan;29(1):189-97
14992278
Adv Exp Med Biol. 2003;526:515-25
12908638
Neurosci Lett. 2008 May 2;436(1):19-22
18375059